StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Total Liver Disease Franchise Product Sales by Quarter

Total Liver Disease Franchise Product Sales — Worldwide YoY growth (%) (%)

QuarterlyAnnual

Gilead Sciences Total Liver Disease Franchise Product Sales: 10.0% in Q2 2026, up 14.0 pts from a year earlier.

Latest, Q2 2026
10.0%
Period ended Jun 30, 2026
Change on a year earlier
+14.0 pts
-4.0% in Q2 2025
History
14 quarters
Since Q1 2023
Sources
14
Documents cited below

Where the Q2 2026 figure comes from

“|| Liver Disease | 877 | 795 | 10% | 1,644 | 1,553 | 6%”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗

Reported in Form 8-K Total Revenue Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Liver Disease Franchise Product Sales — Worldwide YoY growth (%) (%)Year on yearSource
Q2 2026Jun 30, 202610.0%+14.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20261.0%-2.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 202517.0%+13.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 202512.0%+8.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025-4.0%-21.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2025Mar 31, 20253.0%-6.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 20244.0%+5.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2024Sep 30, 20244.0%+14.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2024Jun 30, 202417.0%+13.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2024Mar 31, 20249.0%+3.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 2023-1.0%–Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 2023-10.0%–Form 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗
Q2 2023Jun 30, 20234.0%–Form 8-K (exhibit991earningspressrel.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 20236.0%–Form 8-K (exhibit991earningspressrel.htm, filed 2023-04-27) ↗

Cite this data

StockData. (2026). Gilead Sciences Total Liver Disease Franchise Product Sales (%), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-total-yoy

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.